The results of a Phase III clinical trial of dasatinib (NCT00744497) are awaited, which will provide the first opportunity to more fully assess the potential of Src inhibition as a strategy to extend survival in patients with PCa-induced bone pain. The gene discussed is SRC; the disease is posterior cortical atrophy.